Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von JREMY 

Charles River Labs Intl diskutieren

Charles River Labs Intl

WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

220,60 €
0,96 %

Einschätzung Buy
Rendite (%) 188,37 %
Kursziel 133,00
Veränderung
Endet am 04.11.21

Buy with target price 133.0

Einschätzung Buy
Rendite (%) 11,30 %
Kursziel 227,00
Veränderung
Endet am 10.08.24

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at JPMorgan Chase & Co. from $225.00 to $250.00. They now have an "overweight" rating on the stock.
Ratings data for CRL provided by MarketBeat

Charles River Laboratories International, Inc. (NYSE: CRL) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) 16,84 %
Kursziel 257,73
Veränderung
Endet am 22.09.24

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Wells Fargo & Company from $280.00 to $275.00. They now have an "overweight" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) 38,79 %
Kursziel 201,48
Veränderung
Endet am 09.11.24

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at UBS Group AG from $250.00 to $215.00. They now have a "buy" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) 4,11 %
Kursziel 246,65
Veränderung
Endet am 20.12.24

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at JPMorgan Chase & Co. from $210.00 to $270.00. They now have an "overweight" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,16 %
Kursziel 259,70
Veränderung
Endet am 15.02.25

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at JPMorgan Chase & Co. from $270.00 to $280.00. They now have an "overweight" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,16 %
Kursziel 248,57
Veränderung
Endet am 15.02.25

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Robert W. Baird from $252.00 to $268.00. They now have an "outperform" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,16 %
Kursziel 269,47
Veränderung
Endet am 15.02.25

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at UBS Group AG from $270.00 to $290.00. They now have a "buy" rating on the stock.
Ratings data for CRL provided by MarketBeat

Einschätzung Buy
Rendite (%) -3,16 %
Kursziel 246,00
Veränderung
Endet am 15.02.25

Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $260.00 to $265.00. They now have an "outperform" rating on the stock.
Ratings data for CRL provided by MarketBeat